Predict your next investment

HEALTHCARE | Biotechnology
idogen.com

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

6/12/2015

Market Cap

0.04B

About Idogen

Idogen is a Swedish biotechnology company based in Lund. The company develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues. Idogen’s intention is to revolutionize the treatment of several disorders in which the body’s immune system does not function as it should, and for which there is a major unmet medical need – such as in autoimmune diseases, organ transplant rejection and in patients who have developed anti-drug antibodies.

Idogen Headquarter Location

Medicon Village Scheelevägen 2

Lund, 223 81,

Sweden

+46 (0) 46 275 63 30

Latest Idogen News

Idogen : provides update on timelines for the development of the tolerogenic cell therapy IDO 8

Sep 15, 2020

0 Message : *Required fields Idogen AB ('Idogen') is today announcing that the company is postponing the planned start of the first clinical trial of the tolerogenic cell therapy IDO 8 from the first to the second half of 2021. This is due to temporary limitations in capacity at the manufacturing partner Radboud University Medical Center as a result of the COVID-19 pandemic. Following the successful establishment and scaling up of manufacturing during the spring, work is now in progress to document the processes prior to an application for the commencement of clinical trials in patients with haemophilia A. The company expects to file the application with the Swedish Medical Products Agency towards the end of the first half of 2021. During spring 2020, the establishment and scaling up was successfully carried out of the manufacturing process for Idogen's unique cell therapy products at the company's GMP-certified partner, Radboud University Medical Center in the Netherlands. Extensive work is currently in progress aimed at documenting and qualifying the processes prior to the planned first clinical trial of IDO 8. However, these efforts were impacted by capacity limitations arising as a result of the ongoing COVID-19 pandemic and the unit's close link to hospital activities. Idogen's manufacturing partner has, however, recently been able to once again increase its capacity and is now striving to minimise the incurred delay, without compromising on the high standards imposed on quality. Alongside of this production work, Idogen is continuing its interaction with the Swedish Medical Products Agency to ensure that its application to start clinical studies is in line with the Agency's requirements. Idogen estimates that such an application can be filed towards the end of the first half of 2021. The recently announced recruitment of Idogen's new Chief Regulatory Officer, Vicki Venizelos, who has many years of experience within regulatory affairs in general, and within cell therapy in particular, will strengthen the company in this important work. 'It is satisfying that Idogens manufacturing partner has succeeded, despite its limited capacity during the COVID-19 pandemic, to establish a successful production process for our cell therapy. We have chosen to make a slight adjustment to the timelines of the project to ensure that we maintain the high standards imposed on quality in the remaining development work. The capacity-related delay at Radboud University Medical Center results in a delayed start to the clinical study, but we see good opportunities to shorten the time for patient recruitment by using several trial centers that operate in parallel.Our previous assessment was that the clinical study can be completed in December 2022 and at present we see good opportunities to complete it during the first quarter of 2023, says Anders Karlsson, CEO of Idogen. For further information, please contact: Anders Karlsson, CEO, Idogen AB Tel: +46 70 918 00 10 E-mail: anders.karlsson@idogen.com Certified Adviser The company's Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm; tel: +46 (0)8-463 80 00, e-mail: certifiedadviser@penser.se. Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissues. The company's most advanced project, IDO 8, is designed to restore the efficacy of haemophilia drugs in patients who have developed neutralising antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favourable safety profile and long-lasting effect. The potential for a short-term treatment to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Idogen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Idogen is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Idogen Patents

Idogen has filed 8 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/25/2014

12/12/2017

Immunology, Immune system, Clusters of differentiation, Autoimmune diseases, EC 1.13.11

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/25/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/12/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Immunology, Immune system, Clusters of differentiation, Autoimmune diseases, EC 1.13.11

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.